A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Athenex
- 14 Aug 2017 According to an Athenex media release, the company submitted Investigational New Drug (IND) Application of Oraxol to Chinese FDA in July and commenced this trial.The IND application has been accepted by the Chinese FDA for review.
- 19 Jul 2017 According to an Athenex media release, first patient has been dosed.
- 12 May 2017 Status changed from not yet recruiting to recruiting.